Articles, App Notes, Case Studies, & White Papers

  1. Solid Form Screening, Rapid Formulation Selection To Meet Tight Timelines

    A comprehensive approach to evaluating drug molecules for the selection of a lead solid form and formulation can significantly accelerate development timelines and limit risks in later development.

  2. What's Standing In The Way Of Mainstream NAMs Adoption? 5/19/2026

    NAM adoption is constrained by inconsistent cell sourcing, limited standardization, and regulatory uncertainty — barriers that must be addressed to enable reproducible evidence and regulatory trust.

  3. Realizing The Promise Of New Approach Methodologies (NAMs) 2/27/2026

    NAMs are transforming risk assessment. Learn how integrating advanced in vitro models and computational tools can improve efficiency, reduce costs, and strengthen regulatory decision-making.

  4. Combining Powdose® And Diffucaps® For Precise Solid Oral Dosing 6/30/2025

    Combining POWDOSE® and Diffucaps® enables precise, individualized solid oral dosing—improving drug delivery, patient compliance, and therapeutic outcomes in personalized medicine applications.

  5. How Recent Trends Impact Bringing Your Molecule To Market 7/9/2024

    With accelerated approval times, growing competition between drugs, and a shift from hospital to home care, you’re under pressure to develop a delivery device in parallel with your drug.

  6. Enabling Subcutaneous Delivery For Improved Patient Compliance 3/3/2025

    The ability to administer high doses of biologics subcutaneously offers numerous benefits, including reduced treatment burden, improved patient convenience, and increased adherence to treatment regimens.

  7. Key Considerations When Choosing A Device For Dry Powder Nasal Delivery 10/21/2024

    Building on previous discussions, here we discuss the benefits of nasal delivery and the challenges of developing dry powder formulations by focusing on key devices that can be used for delivering dry powder nasal dosage forms.

  8. The Path To Commercialization For Wearable Drug Delivery Devices

    Explore the evolution of the wearable drug delivery market, including the route to commercialization and the challenges faced.

  9. Navigating Regulatory Challenges In Oligonucleotide Therapeutics 12/12/2024

    Oligonucleotide therapies offer precise treatments for genetic disorders and chronic diseases. They face unique regulatory challenges but hold great promise, especially when combined with FDA engagement.

  10. De-Risking The Transition From Vial To Drug-Device Combination Product 7/25/2025

    When transitioning from a vial to a combination product system, the best approach is to have a holistic de-risk strategy with an intentional focus on the patient, the plan, and the product.